Aisling Capital Management LP
In its 13F for Q1 2024 (holdings as of March 31, 2024, filed May 14, 2024), Aisling Capital Management LP reported 16 stock positions worth $295.5 million. Its top holding was Bridgebio Pharma (BBIO) at 63.5% of the portfolio, followed by Syndax Pharmaceuticals (SNDX, 8.3%) and Verona Pharma (VRNA, 6.1%). Compared with Q4 2023, it opened 1 new position and sold out of 1. The biggest buy was a new position in Calcimedica (CALC) and the biggest sale an exit from Atreca Class A (BCEL).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0001766721
- Portfolio Value
- $295.5M (Q1 2024)
- SEC Filing
- 0001766721-24-000003 ↗ filed May 14, 2024
Holdings Value
Holdings 16 stocks · $295.5M
| BBIO Bridgebio Pharma Inc. | 63.50% | 6,068,125 | $187.6M | No change |
| SNDX Syndax Pharmaceuticals Inc. | 8.26% | 1,025,000 | $24.4M | No change |
| VRNA Verona Pharma Ltd. | 6.07% | 1,115,352 | $17.9M | No change |
| ELEV Elevation Oncology Inc. | 4.92% | 2,834,910 | $14.5M | No change |
| BMEA Biomea Fusion Inc. | 4.04% | 798,757 | $11.9M | No change |
| GLUE Monte Rosa Therapeutics Inc. | 3.51% | 1,472,331 | $10.4M | No change |
| NUVB Nuvation Bio Inc. | 3.13% | 2,541,009 | $9.2M | No change |
| CMPS Compass Pathways PLC | 2.72% | 964,500 | $8.0M | No change |
| PSTX Poseida Therapeutics Inc. | 1.13% | 1,043,267 | $3.3M | No change |
| CALC Calcimedica Inc. | 0.73% | 521,114 | $2.2M | New |
| RENEO PHARMACEUTICALS INC | 0.50% | 886,075 | $1.5M | No change |
| MRKR Marker Therapeutics Inc. | 0.46% | 314,286 | $1.4M | No change |
| AVROBIO INC | 0.44% | 1,009,779 | $1.3M | No change |
| SPRB Spruce Biosciences Inc. | 0.32% | 1,205,511 | $948K | No change |
| ACRS Aclaris Therapeutics Inc. | 0.18% | 434,455 | $539K | No change |
| VIRX Viracta Therapeutics Inc. | 0.10% | 288,571 | $294K | No change |
Portfolio Sells Q4 2023 → Q1 2024
| BCEL Atreca Inc. Class A | Sold out | 0.00% | −0.02 |
Portfolio Buys Q4 2023 → Q1 2024
| CALC Calcimedica Inc. | New | 0.73% | +0.73 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 14 | $471.6M | BBIO, GLUE, SNDX, CMPS, BCAX |
| Q1 2026 | 13 | $476.3M | BBIO, SNDX, GLUE, BCAX, BBOT |
| Q4 2025 | 13 | $478.9M | BBIO, SNDX, GLUE, BCAX, CMPS |
| Q3 2025 | 14 | $456.4M | BBIO, VRNA, SNDX, NUVB, GLUE |
| Q2 2025 | 13 | $359.7M | BBIO, VRNA, SNDX, GLUE, BCAX |
| Q1 2025 | 13 | $288.5M | BBIO, VRNA, SNDX, BCAX, GLUE |
| Q4 2024 | 15 | $281.8M | BBIO, VRNA, SNDX, GLUE, PSTX |
| Q3 2024 | 16 | $261.1M | BBIO, VRNA, SNDX, BCAX, BMEA |
| Q2 2024 | 15 | $231.1M | BBIO, SNDX, VRNA, ELEV, NUVB |
| Q1 2024 | 16 | $295.5M | BBIO, SNDX, VRNA, ELEV, BMEA |